Gyre Therapeutics, Inc. Derivative, Gain (Loss) on Derivative, Net
Gyre Therapeutics, Inc. (GYRE) reported Derivative, Gain (Loss) on Derivative, Net of $1.06 million for the 12-month period ending 2016-12-31, per its 10-K filed 2018-03-19.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeGainLossOnDerivativeNet · last filed 2018-03-19
- Gyre Therapeutics, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2016-12-31 was $21.00K.
- Gyre Therapeutics, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2016-09-30 was $99.00K, a 86.62% decline year-over-year.
- Gyre Therapeutics, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2016-06-30 was $62.00K.
- Gyre Therapeutics, Inc. derivative, gain (loss) on derivative, net for the quarter ending 2016-03-31 was $875.00K.
- Gyre Therapeutics, Inc. derivative, gain (loss) on derivative, net for fiscal 2016 was $1.06M, a 336.78% increase from fiscal 2015.
- Gyre Therapeutics, Inc. derivative, gain (loss) on derivative, net for fiscal 2015 was $242.00K.
| Period end | Derivative, Gain (Loss) on Derivative, Net 3 month | Derivative, Gain (Loss) on Derivative, Net 6 month | Derivative, Gain (Loss) on Derivative, Net 9 month | Derivative, Gain (Loss) on Derivative, Net 12 month |
|---|---|---|---|---|
| 2016-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | $120.00K derived: sum of 2 quarters · filed 2018-03-19 | $182.00K derived: sum of 3 quarters · filed 2018-03-19 | $1.06M 10-K · filed 2018-03-19 |
| 2016-09-30 | $99.00K 10-Q · filed 2016-11-03 | $161.00K derived: sum of 2 quarters · filed 2017-08-03 | $1.04M 10-Q · filed 2017-11-02 | $538.00K derived: sum of 4 quarters · filed 2017-08-03 |
| 2016-06-30 | $62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $937.00K 10-Q · filed 2017-08-03 | $439.00K derived: sum of 3 quarters · filed 2017-08-03 | $1.18M derived: sum of 4 quarters · filed 2017-08-03 |
| 2016-03-31 | $875.00K 10-Q · filed 2017-05-11 | $377.00K derived: sum of 2 quarters · filed 2017-05-11 | $1.12M derived: sum of 3 quarters · filed 2017-05-11 | |
| 2015-12-31 | -$498.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | $242.00K derived: sum of 2 quarters · filed 2017-03-08 | $242.00K 10-K · filed 2017-03-08 | |
| 2015-09-30 | $740.00K 10-Q · filed 2016-11-03 | $740.00K 10-Q · filed 2016-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |